Welcome to AZ MedX

AstraZeneca’s Respiratory & Immunology medical resource centre for healthcare professionals

Discover the latest advances and approaches in asthma, COPD and more

This site is intended for the use of Healthcare Professionals only. By clicking the link below you declare and confirm:

If you are not a Healthcare Professional, please follow this link for information on global patient resources.

Let’s work together to improve asthma care

In 2019, the Global Initiative for Asthma (GINA) introduced the most fundamental change in asthma care in 30 years. For safety, GINA no longer recommends short-acting β2-agonist (SABA)-only treatment for adult and adolescent patients with asthma. Inhaled corticosteroid (ICS)-containing treatment is now the preferred medication across all asthma severities [1].

Many patients with asthma overestimate their asthma control and under-use their ICS medications in day-to-day life [2,3]. This highlights the importance of effectively communicating the rationale behind the change in GINA recommendations, to ensure patient confidence and adherence when initiating a new treatment plan.

Listen to Dr Peter Lin, Director of Primary Care Initiatives at the Canadian Heart Research Centre, talk about how to explain the benefits of the new GINA strategy to patients.

GINA recommends that a patient’s asthma management should be reviewed every 1-3 months when initiating a treatment, and every 3-12 months thereafter [1]. There are several tools available to facilitate your discussions with patients in regard to their asthma management and potential SABA over-use, such as:

Asthma care is changing.

Look out for the Asthma Revolution in your country, and join the conversation with other healthcare professionals.


[1] Global Initiative for Asthma. Pocket Guide for Asthma Management and Prevention (for adults and children older than 5 years). 2021. Available from: https://ginasthma.org/reports/.

[2] Price D et al. NPJ Prim Care Respir Med. 2014;24:14009.

[3] Williams LK et al. J Allergy Clin Immunol. 2011;128:1185-1191.e2.

You are now leaving: http://azmedx.com/

By following this link you will be leaving the AZ MedX website.

Please note that AstraZeneca does not take responsibility for the content displayed on other websites.

Continue Return to AZ MedX